

SEP 1 7 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Michael O' Malley President Cosmedent Company Incorporated 401 North Michigan Avenue Suite 2500 Chicago, Illinois 60611

Re: K030832

Trade/Device Name: Primosplint System

Regulation Number: Unclassified

Regulation Name: None Regulatory Class: None Product Code: MQC Dated: June 30, 2003 Received: July 1, 2003

## Dear Mr. O' Malley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal</u> Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Susan Runner, DDS, MA

Interim Director

Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## INDICATIONS FOR USE STATEMENT

510(kK) Number (if known):	K030832.
Device Name:	Primosplint System
Indication for Use:	
<u>Use for</u> :	
Primosplint System should be us splints.	sed for producing functional therapy and bite
DESCRIPTION OF DEVICE	
· · · · · · · · · · · · · · · · · · ·	eveloped for functional therapy bite splints and ed outside of the mouth from stone models. It by the use of a glaze.
Appendix B.  (Division Signature Division of Augustion Continuous)	is of Primosplint System may be found in Many SouthSk n-Off) nesthesiology, General Hospital, ntrol, Dental Devices her: 15030832
(PLEASE DO NO	Γ WRITE BELOW THIS <del>LIN</del> E)
Concurrence of CDRH,	Office of Device Evaluation (ODE)
Prescription Use	OR Over-the Counter Use